



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Mouse anti-PSA, clone ER-PR8

Clone no. ER-PR8

MONOSAN Ready To Use

---

Product name	Mouse anti-PSA, clone ER-PR8
Host	Mouse
Applications	IHC-P
Species reactivity	human
Conjugate	-
Immunogen	Unknown or proprietary to MONOSAN and/or its suppliers
Isotype	IgG1-k
Clonality	Monoclonal
Clone number	ER-PR8
Size	7 ml
Concentration	n/a
Format	-
Storage buffer	Tris Buffer, pH 7.3-7.7, containing 1% BSA and <0.1% Sodium Azide
Storage until expiry date	2-8°C

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES

Mouse anti-PSA, clone ER-PR8

Clone no. ER-PR8

MONOSAN Ready To Use

---

**Additional info**

Prostate-Specific Antigen (PSA) is a 33 kDa protein primarily produced by the prostatic epithelium and the epithelial lining of the periurethral glands. PSA is strongly expressed in both normal and neoplastic prostatic tissue. Although PSA can be considered prostate-specific, PSA and/or PSA gene expression has been detected at low levels in some extra-prostatic tissues such as normal breast tissue, breast tumors, endometrium, adrenal neoplasms and renal cell carcinomas. Anti-PSA is most useful in determining the prostatic origin of carcinomas in non-prostate tissues (metastatic disease) using IHC techniques. This product is best used in conjunction with a panel of antibodies as, up to 27% of prostate carcinoma cases (predominantly poorly differentiated carcinomas) can be negative for this marker.

**References**

1. Polascik TJ, et al. J Urol. 1999; 162:293
2. Stenman UH, et al. Semin Cancer Biol. 1999; 9:83-93
3. Alanen KA, et al. Path Res Pract. 1996; 192:233-237
4. Varma M, et al. Histopathology. 2005; 47:1-16
5. -

**FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES**